SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Outcome Of Board Meeting
With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2024 which commenced at 11.50 am and concluded at 3.45 pm has inter alia considered and approved audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2024. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q4 & year ended 31 March 2024 Conference Call to be held on Friday, May 24, 2024 at 1:00 PM IST SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Consideration Of Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St March 2024
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Thursday, 23 May 2024 inter alia to transact the following business items: 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2024 2. Recommendation of Dividend, if any for the financial Year ended 31 March 2024 SHILPA MEDICARE LTD. - 530549 - Clinical Trail Announcement For SML 007
Clinical Trial Announcement for SML 007 SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order
NLCT order on Merger of Shilpa Therapeutics Private Limited, a wholly owned subsidiary with Shilpa Medicare Limited, Holding company SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shilpa Medicare Ltd QIP SHILPA MEDICARE LTD. - 530549 - Compliance Certificate Under Regulation 40(10) SEBI (LODR) Regulations, 2015.
Pursuant to Regulation 40(9) of the Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the certificate dated April 19, 2024, for the year ending March 31, 2024, issued by CS D S Rao, Practicing Company Secretary, CP No. 14487. SHILPA MEDICARE LTD. - 530549 - Compliance Certificate For The Period Ending March 31, 2024.
Pursuant to Regulation 7(3) of SEBI (LODR) Regulations, 2015, please find enclosed a certificate dated April 18, 2024, for the year ending March 31, 2024. Certifying that all activities in relation to both physical and electronic share transfer facilities were maintained by "M/s Kfin Technologies Limited" (SEBI Registration No. INR000000221) the Registrar and Share Transfer Agent of Shilpa Medicare Limited.
Shilpa Medicare shares touch 52-week high on GMP Certification from Ages, Austria
Shilpa Medicare Share Price | Earlier in this month, the company had raised Rs 500 crore through a Qualified Institutional Placement (QIP). SHILPA MEDICARE LTD. - 530549 - Launch Of Pemetrexed Injection, 100Mg/10 Ml, 500 Mg/50 Ml, 1000 Mg/100 Ml (NDA)
Launch of Pemetrexed Injection, 100mg/10 ml, 500 mg/50 ml, 1000 mg/ 100 ml (NDA)